[177Lu]Lu-XT381 / Sinotau Pharma - LARVOL DELTA

Phase I Dose Escalation & Expansion Study of [177Lu]Lu-XT381 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (ESMO 2026) - No abstract available

Clinical • Metastases • P1 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Randomized, Dose-Optimization Phase II Study of [177Lu]Lu-XT381 in First-Line Metastatic Castration-Resistant Prostate Cancer (ESMO Asia 2026) - No abstract available

Clinical • Metastases • P2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

XT381: A Next-Generation PSMA-Targeted Radioligand with Enhanced Tumor Retention and Efficacy (EANM 2026) - "[177Lu]Lu-XT381 is more efficacious than [177Lu] Lu-PSMA-617 in inhibiting tumor growth, while maintaining a comparable safety margin."

Clinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • FOLH1